MUMBAI, India, Sept. 7 -- Intellectual Property India has published a patent application (202617084384 A) filed by The Johns Hopkins University on July 09, 2026, for Dendrimer Compositions For The Treatment Of Atherosclerosis, Obesity, And Metabolic Syndromes.
Inventors include Kannan, Sujatha; Rangaramanujam, Kannan; Santhanam, Lakshmi; Almodiel, Diego; and Liyanage, Wathsala.
The application for the patent was published on September 04, 2026, under issue no. 36/2026.
Abstract: Dendrimer-drug compositions have been developed that not only target the reactive inflammatory cells/macrophages in the plaque, but also in the adipose tissue, delivering drugs in a targeted manner to simultaneously and independently address both atherosclerosis and obesity, and associated metabolic disorders. The dendrimers are preferably glucose dendrimers, hydroxyl-terminated PAMAM dendrimers, or sugar-modified dendrimers, most preferably glucose dendrimers. The drugs are preferably a PPAR-a agonist; a PPAR-? agonist; a dual PPAR agonist (e.g., a PPAR- a/? agonists); a GLP-1 receptor agonist (e.g., semaglutide); a metformin; an SGLT2 agonist, a GIP-1 receptor agonist or antagonist; a dual GLP-1/GIP-1 receptor agonist (e.g., tirzepatide); a mitochondrial uncoupler (e.g., niclosamide); or a combination thereof. These compositions have the ability to overcome the side effects of current drugs for obesity and heart disease, and open new avenues in addressing these disorders through targeting of selective cells.
Disclaimer: Curated by HT Syndication.
